Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 13/20 | 0.69 |
| ▸ | EZH1 | Q92800 | 11/20 | 0.69 |
| ▸ | EED | O75530 | 5/20 | 0.69 |
| ▸ | SUZ12 | Q15022 | 5/20 | 0.69 |
| ▸ | RBBP4 | Q09028 | 4/20 | 0.69 |
| ▸ | AEBP2 | Q6ZN18 | 4/20 | 0.69 |
| ▸ | RBBP7 | Q16576 | 3/20 | 0.69 |
| ▸ | PRMT3 | O60678 | 2/20 | 0.69 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.69 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17734425 | 0.90 | EZH2 (0.70) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL24227161 | 0.89 | EZH2 (0.70) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL16115918 | 0.86 | EZH2 (0.72) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL17734379 | 0.85 | EZH2 (0.72) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL17734424 | 0.85 | EZH2 (0.67) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL2592678 | 0.85 | EZH2 (0.81) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL17734378 | 0.84 | EZH2 (0.67) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL17734364 | 0.84 | EZH2 (0.72) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL2595575 | 0.84 | EZH2 (0.74) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL20621449 | 0.82 | EZH2 (0.67) | EZH2EZH1EEDSUZ12RBBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016073956-A1 | EZH2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016073903-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-05-12 | — | — | WO | disclosed |